top of page
external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus. 
Explore the latest updates from the life science industry.

London Biotechnology Show_Register Now.png

Popular Content.

PHARMA

LEO Pharma strengthens psoriasis portfolio in China with NMPA approval of Enstilar®

NMPA approval of Enstilar® marks a key expansion for LEO Pharma in China, bringing a widely used topical psoriasis treatment to an estimated 6.5 million patients amid growing demand for innovative dermatology care.

 Featured Articles. 

7-format11240.jpg
BIOTECH

The Future of Medicine Is In Your DNA

7-format11240.jpg
PHARMA

Inside Nxera Pharma’s Next-Generation Biopharma Model

7-format11240.jpg
BIOPROCESSING

FUJIFILM Biotechnologies Launches UK’s Largest Single-Use Biomanufacturing Facility

7-format11240.jpg
BIOTECH

Basecamp Research Launches the Trillion Gene Atlas

7-format11240.jpg
BIOTECH

Antiverse Targets Drug Discovery's "Undruggable" Frontier with AI-Driven Antibodies

7-format11240.jpg
HEALTH

Killing Mosquitoes With the Smell of Flowers

7-format11240.jpg
PHARMA

Pharma & Biotech Quality Summit 2026

7-format11240.jpg
SUSTAINABILITY

Engineering Crops From the Inside Out

7-format11240.jpg
BIOTECH

PRISM ALS Sets Out to Improve ALS/MND Drug Discovery

 Latest News. 

27th April, 2026

01.

LEO Pharma strengthens psoriasis portfolio in China with NMPA approval of Enstilar®

NMPA approval of Enstilar® marks a key expansion for LEO Pharma in China, bringing a widely used topical psoriasis treatment to an estimated 6.5 million patients amid growing demand for innovative dermatology care.

21st April, 2026

02.

Atelerix Launches STORganoid: Cryo-Free Ambient-Temperature Preservation for Organoids and Spheroids

Atelerix Launches STORganoid: Cryo-Free Ambient-Temperature Preservation for Organoids and Spheroids.

14th April, 2026

03.

Andelyn Biosciences and Evolyra Therapeutics Join Forces to Advance Gene Therapies for Limb-Girdle Muscular Dystrophy

A new CDMO partnership aims to bring clinical-grade AAV gene therapies to patients with LGMD types 2C and 2D, with an IND filing targeted for the second half of 2026

11th April, 2026

04.

CAR-T Therapy Drives Multi-Disease Remission

Single treatment induces sustained remission across three autoimmune conditions, signalling expansion beyond oncology.

Editor's Selects.

Weighing the Cost of Semaglutide

First Human Egg ‘Rejuvenation’ Offers Hope for Older IVF Patients

A Simple Pad Could Transform Cervical Cancer Screening

Inside Nxera Pharma’s Next-Generation Biopharma Model

Stay up-to-date. Connect with BioFocus on LinkedIn or subscribe to our mailing list.

bottom of page